Edwards Lifesciences (NYSE:EW) Given New $88.00 Price Target at Robert W. Baird

Edwards Lifesciences (NYSE:EW) had its target price increased by equities researchers at Robert W. Baird from $83.00 to $88.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s price target would suggest a potential upside of 2.66% from the stock’s previous close.

Other analysts also recently issued research reports about the company. The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, October 31st. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. UBS Group reissued a “neutral” rating on shares of Edwards Lifesciences in a report on Wednesday. Royal Bank Of Canada raised their target price on shares of Edwards Lifesciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Finally, Canaccord Genuity Group reiterated a “hold” rating on shares of Edwards Lifesciences in a report on Friday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $92.09.

Edwards Lifesciences Stock Up 2.1%

EW opened at $85.72 on Friday. The stock has a market cap of $49.74 billion, a price-to-earnings ratio of 36.95, a price-to-earnings-growth ratio of 3.72 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm’s fifty day moving average is $80.75 and its 200 day moving average is $78.68. Edwards Lifesciences has a fifty-two week low of $65.94 and a fifty-two week high of $87.40.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in EW. Norges Bank bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after buying an additional 4,805,819 shares during the period. Nuveen LLC purchased a new stake in Edwards Lifesciences during the 1st quarter valued at $330,881,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Finally, Marshall Wace LLP boosted its stake in Edwards Lifesciences by 127.5% during the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.